

Supplementary Files

S1. Search strategy used in different databases

PubMed	SCOPUS/EMBASE	WHO/Semantic Scholar
ALL ("COVID-19" OR "COVID-2019" OR "severe acute respiratory syndrome coronavirus 2" OR "severe acute respiratory syndrome coronavirus 2" OR "2019-nCoV" OR "nCoV" OR "SARS-CoV-2" OR "2019nCoV" OR "coronavirus") AND ALL ("clinical for epidemiological characterization" OR "Symptom" OR "Symptoms") AND ALL ("comorbidity" OR "comorbidities" AND full text[<i>sb</i>] AND ("2019/12/31"[<i>PDat</i>] : "2020/04/20"[<i>PDat</i>]) AND Humans[<i>Mesh</i>].	ALL ("COVID-19" OR "COVID-2019" OR "severe acute respiratory syndrome coronavirus 2" OR "severe acute respiratory syndrome coronavirus 2" OR "2019-nCoV" OR "nCoV" OR "SARS-CoV-2" OR "2019nCoV" OR "coronavirus") AND ALL ("clinical for epidemiological characterization" OR "Symptom" OR "Symptoms") AND ALL ("comorbidity" OR "comorbidities") AND (LIMIT-TO (LANGUAGE , "English")) AND (LIMIT-TO (PUBYEAR , 2020)) AND (LIMIT-TO (DOCTYPE , "ar") OR LIMIT-TO (DOCTYPE , "re"))	("COVID-19" OR "COVID-2019" OR "severe acute respiratory syndrome coronavirus 2" OR "severe acute respiratory syndrome coronavirus 2" OR "2019-nCoV" OR "nCoV" OR "SARS-CoV-2" OR "2019nCoV" OR "coronavirus") AND ("clinical for epidemiological characterization" OR "Symptom" OR "Symptoms") AND ("comorbidity" OR "comorbidities")

S2. Characteristics of studies that evaluated the prevalence and correlation of symptoms and comorbidities of the COVID-19 patients.

Authors	Publication Date	Country & Location	Study Design	Mean/ Median Age	Patient No. (n)	Male (n)	Female (n)	Gender	Fever	Cough / Dry cough	Fatigue	Dyspnoea/ Shortness of breath	Headache	Diarrhoea
Wan et al.	21.3.2020	Chongqing, China	N/M	47	135	72	63	Both	0.89	0.77	0.33	0.13	0.33	0.13
Zhang et al.	18.2.2020	Wuhan, China	N/M	57	140	71	69	Both	0.79	0.64	0.64	0.31	N/M	0.13
Xu et al.	19.2.2020	Zhejiang, China	Retrospective	41	62	35	27	Both	0.77	0.81	0.52	N/M	0.34	0.08
Zhu et al.	13.3.2020	Anhui, China	Retrospective	46	32	15	17	Both	0.84	0.66	0.16	N/M	0.03	0.03
Chen et al.	16.02.2020	Wuhan, China	Retrospective	56	21	17	4	Both	0.99	0.80	0.85	0.52	0.10	0.20
Liu et al.	9.02.2020	Shenzhen, China	N/M	60	12	8	4	Both	0.83	0.92	N/M	N/M	N/M	0.17
Chen et al.	26.03.2020	Wuhan, China	Retrospective	62	274	171	103	Both	0.91	0.68	0.50	0.44	0.11	0.28
Mo et al.	16.3.2020	Wuhan, China	Retrospective, single center	54	155	86	69	Both	0.81	0.63	0.73	0.32	0.10	0.05
Liu et al.	07.02.2020	Hubei, China	Retrospective	57	137	61	76	Both	0.82	0.48	0.32	0.19	0.10	0.08
Jin et al.	24.03.2020	Zhejiang, China	Retrospective	46	651	331	320	Both	0.84	0.67	0.18	N/M	0.10	N/M
Wang et al.	17.03.2020	Wuhan, China	Retrospective, single center	56	138	75	63	Both	0.99	0.59	0.70	0.31	0.07	0.10
Yuan et al.	19.03.2020	Hubei, China	Retrospective	60	27	12	15	Both	0.78	0.59	N/M	0.41	N/M	N/M
Guan et al.	28.02.2020	China (30 provinces)	Cohort	47	1099	639	460	Both	0.89	0.68	0.38	N/M	0.14	0.04
Liu et al.	27.03.2020	Hainan, China	Retrospective	68	56	31	25	Both	0.76	0.36	0.09	N/M	N/M	N/M
Zhou et al.	12.03.2020	Wuhan, China	N/M	51	254	115	139	Both	0.84	0.39	0.52	0.04	0.11	N/M
Huang et al.	24.01.2019	Wuhan, China	Cohort	49	41	30	11	Both	0.98	0.76	0.44	0.55	0.08	0.03
Chen et al.	29.01.2019	Wuhan, China	Retrospective, single center	55.5	99	67	32	Both	0.83	0.82	N/M	N/M	0.08	0.02
Du et al.	3.04.2020	Wuhan, China	Retrospective	66	85	62	23	Both	0.92	0.22	0.59	0.71	0.05	0.19
Xu et al.	28.02.2020	Guangzhou, China	N/M	50	90	39	51	Both	0.78	0.63	0.21	N/M	0.04	0.06
Goyal et al.	17.04.2020	New York, USA	Retrospective	62	393	238	155	Both	0.77	0.79	N/M	0.57	N/M	0.24
Barrasa et al.	1.04.2020	Vitoria, Spain	N/M	63	48	27	21	Both	1.00	0.73	N/M	0.88	N/M	N/M
Yan et al.	12.4.2020	USA	Cross sectional	48.5	59	29	29	Both	0.70	0.66	0.81	0.54	0.66	0.48
Gupta et al.	6.04.2020	New Delhi, India	Retrospective, Observational	40	21	14	7	Both	0.43	0.43	N/M	N/M	0.14	N/M
Yang et al.	21.02.2020	Wenzhou, China	Retrospective cohort	45	149	81	68	Both	0.77	0.58	N/M	0.01	0.09	0.07
Han et al.	15.04.2020	Wuhan, China	Retrospective	62.5	206	91	115	Both	0.67	0.26	0.45	N/M	N/M	0.33
Kim et al.	6.04.2020	South Korea	Cohort	40	28	15	13	Both	0.25	0.29	0.11	N/M	0.25	0.11
Wang et al.	15.03.2020	Wuhan, China	Retrospective, single-centre	69	339	166	173	Both	0.92	0.53	0.40	0.41	0.04	0.13
Shi et al.	24.02.2020	Wuhan, China	Retrospective	49.5	81	42	39	Both	0.73	0.59	0.09	0.42	0.06	0.04
Yang et al.	21.02.2020	Wuhan, China	Retrospective, single-centre, Observational	60	52	35	17	Both	0.98	0.77	N/M	0.64	0.06	N/M

N/M: Not Mentioned

S2 (Continued). Characteristics of studies that evaluated the prevalence and correlation of symptoms and comorbidities of the COVID-19 patients.

Authors	Sore Throat	Myalgia/ Muscle Ache	Rhinorrhea	Cough/ Sputum Production	Chest tightness	Chest pain	Nausea	Vomiting	Abdominal Pain	Dizziness	Anorexia	Pharyngalgia	Hemoptysis	Others	No. of Symptoms
Wan et al.	N/M	0.33	N/M	0.09	N/M	N/M	N/M	N/M	N/M	N/M	N/M	0.18	0.03	Loss of appetite-4.4%, Palpitation-3.7%, Retching-3%	13
Zhang et al.	N/M	N/M	N/M	N/M	0.31	N/M	0.17	N/M	0.06	N/M	0.17	N/M	N/M	N/M	9
Xu et al.	N/M	0.52	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	0.03	N/M	7
Zhu et al.	N/M	0.16	N/M	0.16	0.09	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	8
Chen et al.	N/M	0.40	N/M	N/M	0.55	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	8
Liu et al.	N/M	0.33	N/M	N/M	N/M	N/M	0.17	0.17	N/M	N/M	N/M	N/M		Chill- 42%	7
Chen et al.	N/M	0.22	N/M	0.30	0.38	N/M	0.09	0.06	0.07	0.08	0.24	0.04	0.03	N/M	16
Mo et al.	N/M	0.61	N/M	N/M	0.39	0.04	0.04	0.04	0.02	0.02	0.32	N/M		N/M	14
Liu et al.	N/M	0.32	N/M	0.04	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	0.05	Heart palpitation-7%	10
Jin et al.	0.15	0.11	N/M	0.35	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	0.02	Nasal Obstruction-6%,	9
Wang et al.	N/M	0.35	N/M	0.27	N/M	N/M	0.10	0.04	N/M	0.09	0.40	0.17	N/M	N/M	13
Yuan et al.	N/M	0.11	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	4
Guan et al.	0.14	0.15	N/M	0.34	N/M	N/M	0.05	0.05	N/M	N/M	N/M	N/M	0.01	Conjunctival congestion-1%, Nasal congestion-5%, Chills-11.5%, Throat congestion-2%, Tonsil swelling-2%, Rash-0.2%	17
Liu et al.	N/M	N/M	N/M	N/M	0.07	N/M	N/M	0.17	N/M	N/M	N/M	N/M	N/M	Nasal congestion-5%,	6
Zhou et al.	0.06	0.34	N/M	0.42	0.26	N/M	N/M	N/M	N/M	0.07	N/M	N/M	N/M	N/M	10
Huang et al.	N/M	0.44	N/M	0.28	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	0.05	N/M	9
Chen et al.	0.05	0.11	0.04	N/M	N/M	0.02	0.01	0.01	N/M	N/M	N/M	N/M	N/M	N/M	10
Du et al.	N/M	0.17	N/M	0.38	N/M	0.02	N/M	0.05	0.04	N/M	0.57	0.02	N/M	N/M	14
Xu et al.	0.26	0.28	N/M	0.12	N/M	N/M	0.06	0.02	N/M	N/M	N/M	N/M	N/M	Chills-7%	11
Goyal et al.	N/M	0.19	N/M	N/M	N/M	N/M	0.19	0.19	N/M	N/M	N/M	N/M	N/M	N/M	7
Barrasa et al.	N/M	0.04	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	Malaise-44%	5
Yan et al.	0.32	0.63	0.31	N/M	N/M	N/M	0.27	N/M	N/M	N/M	N/M	N/M	N/M	Nasal obstruction 47.5%, Anosmia 68%, Ageusia 71%	13
Gupta et al.	0.24	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	5
Yang et al.	0.14	0.03	N/M	0.32	0.10	0.03	0.01	0.01	N/M	N/M	N/M	N/M	N/M	Chill-14%, Snotty-3%	14
Han et al.	N/M	0.21	N/M	N/M	0.24	N/M	N/M	0.12	0.04	N/M	N/M	0.06	N/M	Poor apitite-34%	11
Kim et al.	0.29	0.25	0.07	0.21	N/M	N/M	N/M	N/M	0.04	N/M	N/M	N/M	N/M	N/M	10
Wang et al.	N/M	0.05	N/M	0.28	0.26	N/M	0.04	N/M	N/M	0.04	0.28	0.04	N/M	N/M	13
Shi et al.	N/M	N/M	0.26	0.19	0.22	N/M	N/M	0.05	N/M	0.02	0.01	N/M	N/M	N/M	12
Yang et al.	N/M	0.12	0.06	N/M	N/M	0.02	N/M	0.04	N/M	N/M	N/M	N/M	N/M	Malaise-35%, Arthralgia-2%	10

N/M: Not Mentioned

S2 (Continued). Characteristics of studies that evaluated the prevalence and correlation of symptoms and comorbidities in the nCOVID-19 patients.

Authors	Diabetes	Hypertension	Cardiovascular Disease	Coronary heart disease	Cerebrovascular disease	COPD /Lung disease	Chronic liver disease	Chronic Renal disease	Chronic Kidney disease	Malignancy	ARDS	Others	No. of Comorbidities
Wan et al.	0.09	0.10	0.05	N/M	N/M	0.007	0.02	N/M	N/M	0.03	N/M	N/M	6
Zhang et al.	0.12	0.30	N/M	0.05	N/M	0.014	0.06	0.01	N/M	N/M	N/M	Gastric ulcer & Hyperlepedemia-5%, Thyroid disease-3.6%, Urolithiasis-2.1%, Arrhythmia-3.6%, Cholilithiasis-4.3%	12
Xu et al.	0.02	0.08	N/M	N/M	0.02	0.020	0.11	0.02	N/M	N/M	N/M	N/M	6
Zhu et al.	0.13	0.22	N/M	0.06	0.03	0.060	0.06	0.03	N/M	N/M	N/M	Mental disorder- 3%, Tumor-6%	9
Chen et al.	0.14	0.24	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	2
Liu et al.	0.08	0.25	N/M	0.33	N/M	0.080	N/M	0.08	N/M	N/M	N/M	Bacterial co infection-17%, Pneumonia-100%,	7
Chen et al.	0.17	0.34	0.08	N/M	0.01	0.070	N/M	N/M	0.01	0.03	N/M	HBV infection-4%, Metabolic arthritis & Autoimmune disease & Gastro Intestinal disease- 1%	11
Mo et al.	0.10	0.24	0.10	N/M	0.05	0.030	0.05	0.04	N/M	0.05	N/M	Tuberculosis-2%, HIV-1%	10
Liu et al.	0.10	0.10	0.07	N/M	N/M	0.015	N/M	N/M	N/M	0.02	N/M	N/M	5
Jin et al.	0.07	0.15	N/M	0.01	N/M	0.002	0.04	0.01	N/M	0.01	N/M	Immunosuppression-0.17%,	8
Wang et al.	0.10	0.31	0.15	N/M	0.05	0.030	0.03	N/M	0.03	0.07	N/M	HIV infection-1%	9
Yuan et al.	0.22	0.19	0.11	N/M	N/M	N/M	N/M	N/M	N/M	N/M	0.41	Tumor & Cerebral infraction & Chronic gastric- 4%	9
Guan et al.	0.07	0.15	N/M	0.03	0.01	0.010	N/M	0.01	N/M	0.01	N/M	Hepatitis B Infection-2%, Immune deficiency-0.2%,	9
Liu et al.	0.07	0.17	N/M	0.11	N/M	N/M	0.06	N/M	0.03	N/M	N/M	Persistent arterial fibrillation-6%,	6
Zhou et al.	0.10	0.25	0.05	0.07	N/M	0.020	0.01		N/M	0.01	N/M	HIV infection-0.4%,	8
Huang et al.	0.20	0.15	0.15	N/M	N/M	0.020	0.02	N/M	N/M	0.02	N/M	N/M	6
Chen et al.	N/M	N/M	N/M	N/M	N/M	N/M	N/M	0.03	N/M	N/M	0.17	Acute Respiratory Injury-8%, Septic shock-4%, Pneumonia-1%	5
Du et al.	0.22	0.38	0.08	0.12	N/M	0.020	0.06	N/M	0.04	0.07	N/M	N/M	8
Xu et al.	0.06	0.19	0.03	N/M	N/M	0.010	N/M	N/M	N/M	0.02	N/M	Tuberculosis-2%,	6
Goyal et al.	0.25	0.50	N/M	0.14	N/M	0.050	N/M	N/M	N/M	N/M	N/M	Asthama-12.5%, Obesity-35%	6
Barrasa et al.	0.19	0.44	N/M	0.10	N/M	0.380	N/M	N/M	N/M	N/M	1.00	Obesity-48%, Immunosuppression-3%	7
Yan et al.	0.09	0.14	0.05	N/M	N/M	0.050	N/M	N/M	N/M	0.04	N/M	Allergic rhinitis-34%, Sinus disease 3%	7
Gupta et al.	0.14	0.24	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	Anxiety-5%, Hypothyroidism-5%, Migrane-5%, Obstructive sleep aponea-5%	6
Yang et al.	N/M	N/M	0.19	N/M	0.19	N/M	N/M	N/M	N/M		N/M	Respiratory system disease - 0.67%, Digestive system disease- 5%, Endocrine disease- 6%	5
Han et al.	0.10	0.27	N/M	N/M	0.08	0.040	N/M	N/M	N/M	N/M	N/M	N/M	4
Kim et al.	0.07	N/M	N/M	N/M		N/M	0.04		N/M	0.04	N/M	Obesity-18%, Asthama-4%	5
Wang et al.	0.16	0.41	0.16	N/M	0.06	0.060	0.01	N/M	0.04	0.04	N/M	Autoimmune disease-1.5%	9
Shi et al.	0.12	0.15	0.10	N/M	0.07	0.110	0.09	0.04	N/M	0.05	N/M	N/M	8
Yang et al.	0.35	N/M	0.23	N/M	N/M	N/M	0.29	N/M	0.29	N/M	0.67	Urinary tract infection-2%, Gastrointestinal haemorrhage-4%	7


N/M: Not Mentioned

Overall Meta-analysis of the clinical symptoms and comorbidities

Symptoms


S3. Fever

Meta-analysis of the prevalence of clinical symptom (Fever) in COVID-19 infected patients




S4. Cough / Dry Cough

Meta-analysis of the prevalence of clinical symptom (Cough) in COVID-19 infected patients




S5. Fatigue/Weakness

Meta-analysis of the prevalence of clinical symptom (Fatigue) in COVID-19 infected patients




S6. Dyspnea/Shortness of breath

Meta-analysis of the prevalence of clinical symptom (Dyspnea) in COVID-19 infected patients




S7. Headache


Meta-analysis of the prevalence of clinical symptom (Headache) in COVID-19 infected patients



S8. Diarrhea




S9. Sore Throat




S10. Myalgia/Muscle Ache


Meta-analysis of the prevalence of clinical symptom (Myalgia) in COVID-19 infected patients




S11. Rhinorrhea




S12. Sputum Production/Expectoration




S13. Chest tightness




S14. Chest pain




S15. Nausea




S16. Vomiting




S17. Abdominal Pain




S18. Dizziness




S19. Anorexia



S20. Pharyngalgia




S21. Haemoptysis




Comorbidity

S22. Diabetes




S23. Hypertension

Meta-analysis of the prevalence of clinical comorbidity (Hypertension) in COVID-19 infected patients




S24. Cardiovascular Disease


Meta-analysis of the prevalence of clinical comorbidity (Cardiovascular Disease) in COVID-19 infected patients




S25. Coronary heart disease




S26. Cerebrovascular disease




S27. COPD/Lung disease




S28. Chronic liver disease




S29. Chronic Renal disease




S30. Chronic Kidney disease



S31. Malignancy




S32. ARDS



Subgroup meta-analysis by Age group


Symptoms

S33. Fever




S34. Cough/Dry Cough

Meta-analysis of the prevalence of clinical symptom (Cough/Dry Cough) in COVID-19 infected patients
(stratified according to age group)




S35. Fatigue/weakness

Meta-analysis of the prevalence of clinical symptom (Fatigue/Weakness) in COVID-19 infected patients
(stratified according to age group)




S36. Dyspnea/Shortness of Breath


Meta-analysis of the prevalence of clinical symptom (Dyspnea/Shortness of breath) in COVID-19 infected patients
(stratified according to age group)




Meta-analysis of the prevalence of clinical symptom (Headache) in COVID-19 infected patients
(stratified according to age group)




Meta-analysis of the prevalence of clinical symptom (Myalgia/Muscle Ache) in COVID-19 infected patients
(stratified according to age group)




S39. Rhinorrhea




S40. Sputum Production / Expectoration




S41. Chest Tightness




S42. Nausea




S43. Vomiting




S44. Abdominal Pain



S45. Anorexia




S486. Pharyngalgia



S47. Haemoptysis


Meta-analysis of the prevalence of clinical symptom (Haemoptysis) in COVID-19 infected patients
(stratified according to age group)




Comorbidity

S48. Diabetes


Meta-analysis of the prevalence of clinical comorbidity (Diabetes) in COVID-19 infected patients
(stratified according to age group)




S49. Hypertension




S50. Cardiovascular Disease



S51. Coronary heart disease




S52. Cerebrovascular disease




S53. COPD/Lung disease

Meta-analysis of the prevalence of clinical comorbidity (COPD/Lung Disease) in COVID-19 infected patients (stratified according to age group)




S54. Chronic Liver disease


Meta-analysis of the prevalence of clinical comorbidity (Chronic Liver Disease) in COVID-19 infected patients (stratified according to age group)



S55. Chronic Kidney disease




S56. Chronic Renal Disease



S57. Malignancy


Meta-analysis of the prevalence of clinical comorbidity (Malignancy) in COVID-19 infected patients
(stratified according to age group)




Forest Plot of the Subgroup meta-analysis by Geographical Location

Symptoms

S58. Fever




Meta-analysis of the prevalence of clinical symptom (Cough) in COVID-19 infected patients
(stratified according to geographical location)




S60. Fatigue

Meta-analysis of the prevalence of clinical symptom (Fatigue) in COVID-19 infected patients
(stratified according to geographical location)




S61. Dyspnea / Shortness of breath

Meta-analysis of the prevalence of clinical symptom (Dyspnea) in COVID-19 infected patients
(stratified according to geographical location)




S62. Headache




S63. Diarrhea

Meta-analysis of the prevalence of clinical symptom (Diarrhea) in COVID-19 infected patients
(stratified according to geographical location)




S64. Sore throat

Meta-analysis of the prevalence of clinical symptom (Sore Throat) in COVID-19 infected patients
(stratified according to geographical location)




Meta-analysis of the prevalence of clinical symptom (Myalgia) in COVID-19 infected patients
(stratified according to geographical location)




S66. Nausea

Meta-analysis of the prevalence of clinical symptom (Nausea) in COVID-19 infected patients
(stratified according to geographical location)




S67. Abdominal Pain




Comorbidity:

S68. Diabetes




S69. Hypertension

Meta-analysis of the prevalence of clinical comorbidity (Hypertension) in COVID-19 infected patients
(stratified according to geographical location)




S70. Cardiovascular disease


Meta-analysis of the prevalence of clinical comorbidity (Cardiovascular Disease) in COVID-19 infected patients
(stratified according to geographical location)



S71. Coronary heart disease




S72. COPD / Lung disease




S73. Chronic Liver Disease

Meta-analysis of the prevalence of clinical comorbidity (Chronic Liver Disease) in COVID-19 infected patients
(stratified according to geographical location)




S74. Malignancy

Meta-analysis of the prevalence of clinical comorbidity (Malignancy) in COVID-19 infected patients
(stratified according to geographical location)




Meta-analysis of the prevalence of clinical comorbidity (ARDS) in COVID-19 infected patients
(stratified according to geographical location)




Funnel Plots of the symptoms and comorbidities

Symptoms


S76. Fever




S77. Cough / Dry cough




S78. Fatigue/ Weakness




S79. Dyspnea/ Shortness of breath




S80. Headache




S81. Diarrhea




S82. Sore Throat




S83. Myalgia / Muscle Ache




S84. Rhinorrhea




S85. Sputum Production/Expectoration




S86. Chest Tightness




S87. Chest Pain




S88. Nausea




S89.Vomiting




S90. Abdominal pain




S91. Dizziness




S92. Anorexia



S93. Pharyngalgia




S94. Haemoptysis




Comorbidity


S95. Diabetes




S96. Hypertension




S97. Cardiovascular disease




S98. Coronary heart disease




S99. Cerebrovascular disease




S100. COPD / Lung disease




S101. Chronic Liver disease




S102. Chronic Renal disease



S103. Chronic Kidney disease



S104. Malignancy



S105. ARDS

